A Phase 1 interventional study of ABBV-7828 and Placebo for ABBV-7828 in Healthy Subjects, sponsored by AbbVie. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
This study is to evaluate safety, tolerability, pharmacokinetics and effect of food on ABBV-7828 compared to placebo in healthy adult participants.
AbbVie is the lead sponsor of 953 studies on the registry; 136 are open to participants now.
Of its 350 completed or terminated interventional studies of FDA-regulated products, 210 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Has any clinically significant ECG abnormalities including the following:
Participants will receive single doses of ABBV-7828.
Drug: ABBV-7828
Participants will receive single doses of placebo.
Drug: Placebo for ABBV-7828
Participants will receive ABBV-7828 while in fasting in Period 1 followed by ABBV-7828 after high fat/high calorie meal in Period 2.
Drug: ABBV-7828
Participants will receive ABBV-7828 after a high-fat/high calorie meal in Period 1 followed by ABBV-7828 in fasting conditions in Period 2.
Drug: ABBV-7828
Oral administration
Oral administration
Number of Participants with Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Time frame: Up to approximately 38 days
Maximum Observed Serum Concentration (Cmax) of ABBV-7828
Cmax of ABBV-7828
Time frame: Up to approximately 10 days
Time to Cmax (Tmax) of ABBV-7828
Time to Cmax (Tmax) of ABBV-7828
Time frame: Up to approximately 10 days
Terminal Phase Elimination Rate Constant (Beta) of ABBV-7828
Beta of ABBV-7828
Time frame: Up to approximately 10 days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-7878
AUCt of ABBV-7878
Time frame: Up to approximately 10 days
AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-7878
AUCinf of ABBV-7878
Time frame: Up to approximately 10 days
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AbbVie